You are here: Industry Insights > Opdivo

News List

BMS’ Opdivo cuts risk of melanoma recurrence pharmatimes
June 06, 2018
Bristol-Myers Squibb’s Opdivo, which is being investigated as adjuvant treatment after surgery for stage IIIb/c or IV melanoma patients at high risk of recurrence
Bristol-Myers racks up Opdivo combo data to sell its new biomarker, but will doctors buy it? fiercepharma
June 05, 2018
Bristol-Myers Squibb’s new strategy In lung cancer relies on showing its new biomarker can help predict who benefits most from immunotherapy combinations.
BMS’ Opdivo to Become the First Anti-PD-(L)1 Antibody to Enter China Dopine
April 27, 2018
According to the latest clinical trial data of the CheckMate-078 (NCT02613507, CTR20150767) of Opdivo (nivolumab) conduc
Bristol-Myers Squibb's Opdivo, Yervoy combination cuts risk of progression, death by 42 percent in lung cancer study firstwordpharma
April 17, 2018
Bristol-Myers Squibb announced Monday that the combination of Opdivo and Yervoy reduced the risk of progression or death by 42 percent versus chemotherapy in first-line advanced non-small-cell lung cancer patients whose tumours have high tumour mutation b
Price of blockbuster cancer drug Opidivo to be further reduced by 23 percent in Japan biospectrumasia
March 08, 2018
Opdivo is marketed In Japan by Ono Pharmaceuticals
FDA Expands Bristol-Myers Squibb’s Opdivo Dosing Schedule biospace
March 07, 2018
The U.S. Food and Drug Administration (FDA) expanded the dosing schedule for Bristol-Myers Squibb Company’s Opdivo (nivolumab)
Bristol-Myers Squibb beats Street revenue, EPS estimates in Q4 as Eliquis surges fiercepharma
February 06, 2018
The same day Bristol-Myers Squibb reported a closely watched trial win for cancer combo Opdivo-plus-Yervoy in certain lung cancer patients, the drugmaker announced 2017 results, beating expectations with Opdivo and anticoagulant Eliquis.
Opdivo May Be the First Marketed in China, Chinese Pharmaceutical Enterprises are Catching up Fast! Zhixing
January 17, 2018
Anti-PD-1 monoclonal antibodies are very popular with pharmaceutical enterprises, however, it is hard to find such monoclonal antibody in China.
Bristol-Myers' Lung Cancer Opdivo Trial Stopped Early for Superior Overall Survival biospace
December 04, 2017
Bristol-Myers Squibb has its eyes set on carving out a strong position in the lucrative Chinese lung cancer market.
Lirilumab/Opdivo combo shows ‘no clear evidence of benefit’ .pharmatimes
November 27, 2017
Innate Pharma shares plummeted nearly 50% on Thursday.

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 Next page